Results 31 to 40 of about 40,253 (233)

Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials

Technology in Cancer Research & Treatment, 2022
Purpose: Sorafenib is recommended for patients with hepatocellular carcinoma refractory to transarterial chemoembolization but with unsatisfactory overall survival and tumor response rate.
YeXing Huang MD, LiHong Zhang MD, MinKe He MD, ZhiCheng Lai MD, XiaoYun Bu MD, DongSheng Wen MD, QiJiong Li MD, Li Xu MD, Wei Wei MD, YaoJun Zhang MD, ZhongGuo Zhou MD, MinShan Chen MD, RongPing Guo MD, Ming Shi MD, Anna Kan MD   +14 more
doaj   +1 more source

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. [PDF]

, 2016
Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas.
DuBois, Steven G, Matthay, Katherine K, Vo, Kieuhoa T   +2 more
core   +1 more source

Folate homeostasis of cancer cells affects sensitivity to not only antifolates but also other non-folate drugs: effect of MRP expression

Pteridines, 2013
Sensitivity to antifolates can be decreased by endogenous or exogenous folates. Leucovorin protects cancer patients against toxicity of the dihydrofolate reductase inhibitor methotrexate (MTX), while folic acid is used to protect rheumatoid arthritis ...
Peters Godefridus J., Kathmann Ietje, Lemos Clara, Hooijberg Jan Hendrik, Losekoot Nienke, Jansen Gerrit   +5 more
doaj   +1 more source

OXALIPLATIN/5-FLUOROURACIL/LEUCOVORIN IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER [PDF]

Journal of IMAB, 2013
Objective: Oxaliplatin/ 5- Fluorouracil/ Leucovorin is an effective therapy for patients with metastatic colorectal cancer. The aim of this study was to explore the efficacy and safety of this chemotherapy regimen in the treatment of patient with ...
Deyan N. Davidov
doaj   +1 more source

A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. [PDF]

, 2017
PurposeTumor levels of thymidylate synthase (TS), a target of 5-fluorouracil (5-FU)-based chemotherapy for colorectal cancer, have been studied as a predictive or prognostic biomarker with mixed results.Patients and methodsTumor TS levels were ...
Bertagnolli, Monica M, Colacchio, Thomas A, Compton, Carolyn C, Fuchs, Charles S, Goldberg, Richard M, Hasson, Rian M, Lenz, Heinz-Josef, Mayer, Robert J, Niedzwiecki, Donna, Ogino, Shuji, Redston, Mark, Saltz, Leonard B, Warren, Robert S, Ye, Cynthia   +13 more
core   +1 more source

Safety and Efficiency of Ambulatory High-dose Methotrexate Administration among Hematological Malignancy Patients in a Tertiary Care Center

Journal of Applied Hematology
BACKGROUND: High-dose methotrexate (HDMTX) is commonly used in solid malignancies, such as osteosarcoma, and hematological malignancies, such as acute lymphoblastic leukemia and non-Hodgkin’s lymphoma.
Maged Al-Ammari, Belal Mohammed Albtoosh, Alaa Eldein Yahia, Abdullah Alrajhi, Fouad Alnajjar, Imran Tailor, Mohammed S. Alnoamani, Nawal F. AlShehry, Mohammad Alwadi, Muhned Alhumaid, Mohammed A. Marei, Hassan Alshehri, Mubarak Salem Alghamdi, Kamal K. AlZahrani, Ibraheem Motabi   +14 more
doaj   +1 more source

Comparison of two doses of leucovorin in severe low-dose methotrexate toxicity – a randomized controlled trial

Arthritis Research & Therapy, 2023
Background Leucovorin (folinic acid) is a commonly used antidote for severe toxicity with low-dose methotrexate, but its optimum dose is unclear, varying from 15 to 25 mg every 6-h.
Mudit Bhargava, Chirag Rajkumar Kopp, Shankar Naidu, Deba Prasad Dhibar, Atul Saroch, Alka Khadwal, Tarun Narang, Siddharth Jain, Aastha Khullar, Bidya Leishangthem, Aman Sharma, Susheel Kumar, Shefali Sharma, Sanjay Jain, Varun Dhir   +14 more
doaj   +1 more source

Gemcitabine: Progress in the treatment of pancreatic cancer [PDF]

, 2001
Unresectable pancreatic cancer has a dismal prognosis with a median survival of 3-5 months in untreated disease. Since the introduction of gemcitabine, pancreatic cancer may no longer be regarded a chemotherapy-resistant tumor.
Heinemann, Volker
core   +1 more source

Mature Tertiary Lymphoid Structures Indicate Good Chemotherapy Response and Prognosis in Advanced Colorectal Cancer

Annals of Gastroenterological Surgery, EarlyView.
In advanced colorectal cancer, tumors with mature tertiary lymphoid structures (TLS) exhibited abundant infiltration of CD3‐ and CD8‐positive lymphocytes in both primary and metastatic sites, indicating an activated immune response. The presence of mature TLS was also associated with favorable chemotherapy sensitivity and improved prognosis.
Nobuhiro Hosoi, Chika Komine, Gendensuren Dorjkhorloo, Takuya Shiraishi, Takuhisa Okada, Akihiko Sano, Makoto Sakai, Takehiko Yokobori, Ken Shirabe, Hiroshi Saeki   +9 more
wiley   +1 more source

Christmas Tree-Shaped Microneedles as FOLFIRINOX Spatiotemporal Delivery System for Pancreatic Cancer Treatment

Research, 2022
As an effective combination chemotherapy, FOLFIRINOX regimen (fluorouracil, leucovorin, irinotecan, and oxaliplatin) has shown definite antitumor efficacy for treating pancreatic cancer (PC) nowadays. However, the traditional systematic administration of
Danqing Huang, Xiao Fu, Xiaoxuan Zhang, Yuanjin Zhao   +3 more
doaj   +1 more source